{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","spread":"34.8","upperLimit":"4.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"1.1","spread":"58.0","upperLimit":"4.0","value":"3.0"},{"groupId":"OG002","lowerLimit":"1.9","spread":"44.3","upperLimit":"6.0","value":"2.0"},{"groupId":"OG003","lowerLimit":"1.5","spread":"24.3","upperLimit":"4.3","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Alisertib 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG000","title":"Alisertib 35 mg PIC QD 14D"},{"description":"Alisertib 45 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity to (up 4 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG001","title":"Alisertib 45 mg PIC QD 14D"},{"description":"Alisertib 65 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG002","title":"Alisertib 65 mg PIC QD 14D"},{"description":"Alisertib 90 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity (up to 5 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG003","title":"Alisertib 90 mg PIC QD 14D"}],"paramType":"MEDIAN","populationDescription":"PK evaluable population included all participants for whom there were sufficient dosing and alisertib concentration time data to permit non-compartmental PK analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose","title":"Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1","type":"PRIMARY","unitOfMeasure":"h"}